Caribou Biosciences Inc

NASDAQ CRBU

Data sourced from iex and EODHD
Download Data

Caribou Biosciences Inc Days Payable Outstanding (DPO) 3 year CAGR for the year ending December 31, 2023: 127.11%

Caribou Biosciences Inc Days Payable Outstanding (DPO) 3 year CAGR is 127.11% for the year ending December 31, 2023. The days payables outstanding ratio measures the average number of days it takes for a company to pay its suppliers. It is calculated by dividing accounts payable by the cost of revenue and then multiplying by 365. This ratio indicates the average payment period for suppliers and reflects the efficiency of managing trade payables. A longer period suggests extended payment terms and potential working capital advantages. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Caribou Biosciences Inc Days Payable Outstanding (DPO) for the year ending December 31, 2022 was 114.88, a -92.24% change year over year.
  • Caribou Biosciences Inc Days Payable Outstanding (DPO) for the year ending December 31, 2021 was 1,480.03, a 5,266.75% change year over year.
  • Caribou Biosciences Inc Days Payable Outstanding (DPO) for the year ending December 31, 2020 was 27.58.
NASDAQ: CRBU

Caribou Biosciences Inc

CEO Dr. Rachel E. Haurwitz Ph.D.
IPO Date July 23, 2021
Location United States
Headquarters 2929 7th Street, Berkeley, CA, United States, 94710
Employees 158
Sector Healthcare
Industry Biotechnology
Description

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

StockViz Staff

September 19, 2024

Any question? Send us an email